• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高数量的程序性细胞死亡受体 1 阳性肿瘤浸润淋巴细胞与移植后淋巴组织增生性疾病的早期发病相关。

High numbers of programmed cell death-1-positive tumor infiltrating lymphocytes correlate with early onset of post-transplant lymphoproliferative disorder.

机构信息

Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871, Japan.

Department of Pathology, Kurume University School of Medicine, Kurume, Japan.

出版信息

Int J Hematol. 2021 Jul;114(1):53-64. doi: 10.1007/s12185-021-03129-3. Epub 2021 Mar 25.

DOI:10.1007/s12185-021-03129-3
PMID:33765256
Abstract

Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication of transplantation. In addition to reactivation of Epstein-Barr virus in immunocompromised patients, impaired tumor immunity is suggested to be a risk factor for PTLD. However, it remains unclear whether immune suppressive tumor-infiltrating lymphocytes (TILs) correlate with the occurrence or prognosis of PTLD. We analyzed TILs in 26 patients with PTLD to elucidate the clinicopathological significance of the expression of PD-1 and FoxP3, which are associated with exhausted T-cells and regulatory T-cells (Tregs), respectively. Numbers of PD-1 TILs in the PTLD specimens were significantly higher in patients who developed PTLD early after transplantation (P = 0.0040), while numbers of FoxP3 TILs were not (P = 0.184). There was no difference in overall response rate regardless of the expression of PD-1 or FoxP3. FoxP3 patients tended to have a shorter time to progression compared with FoxP3 patients, especially in the case of FoxP3 patients with diffuse large B-cell lymphoma-subtype PTLD (P = 0.011), while PD-1 patients did not. These results suggest that T-cell exhaustion may be mainly associated with PTLD development, while immune suppression by Tregs may be dominant in enhanced progression of PTLD following disease occurrence.

摘要

移植后淋巴组织增生性疾病(PTLD)是移植的一种危及生命的并发症。除了免疫功能低下患者中 EBV 的再激活外,肿瘤免疫受损被认为是 PTLD 的一个危险因素。然而,免疫抑制性肿瘤浸润淋巴细胞(TILs)是否与 PTLD 的发生或预后相关仍不清楚。我们分析了 26 例 PTLD 患者的 TILs,以阐明与耗竭性 T 细胞和调节性 T 细胞(Tregs)相关的 PD-1 和 FoxP3 的表达的临床病理意义。在移植后早期发生 PTLD 的患者的 PTLD 标本中,PD-1 TIL 的数量明显更高(P=0.0040),而 FoxP3 TIL 的数量则没有(P=0.184)。无论 PD-1 或 FoxP3 的表达如何,总缓解率均无差异。与 FoxP3 患者相比,FoxP3 患者的疾病进展时间更短,尤其是弥漫性大 B 细胞淋巴瘤亚型 PTLD 的 FoxP3 患者(P=0.011),而 PD-1 患者则没有。这些结果表明,T 细胞耗竭可能主要与 PTLD 的发展有关,而 Tregs 的免疫抑制作用可能在疾病发生后 PTLD 的进展中占主导地位。

相似文献

1
High numbers of programmed cell death-1-positive tumor infiltrating lymphocytes correlate with early onset of post-transplant lymphoproliferative disorder.高数量的程序性细胞死亡受体 1 阳性肿瘤浸润淋巴细胞与移植后淋巴组织增生性疾病的早期发病相关。
Int J Hematol. 2021 Jul;114(1):53-64. doi: 10.1007/s12185-021-03129-3. Epub 2021 Mar 25.
2
CD30 expression and survival in posttransplant lymphoproliferative disorders.移植后淋巴组织增生性疾病中 CD30 的表达与生存。
Acta Oncol. 2020 Jun;59(6):673-680. doi: 10.1080/0284186X.2020.1731924. Epub 2020 Feb 27.
3
Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.实体器官和造血干细胞移植后移植后淋巴组织增生性疾病的比较分析揭示了肿瘤微环境的差异。
Virchows Arch. 2021 Jun;478(6):1135-1148. doi: 10.1007/s00428-020-02985-4. Epub 2020 Dec 15.
4
[Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].[移植后淋巴组织增生性疾病:15例临床病理研究]
Zhonghua Bing Li Xue Za Zhi. 2012 Sep;41(9):607-12. doi: 10.3760/cma.j.issn.0529-5807.2012.09.008.
5
Tumor Infiltrating Lymphocytes Predict Survival in Solid Organ Transplant Recipients With Monomorphic Post-transplant Lymphoproliferative Disorders.肿瘤浸润淋巴细胞可预测形态单一性移植后淋巴组织增生性疾病实体器官移植受者的生存情况。
Clin Lymphoma Myeloma Leuk. 2022 Oct;22(10):744-752. doi: 10.1016/j.clml.2022.05.006. Epub 2022 May 23.
6
Is there a difference in post-transplant lymphoproliferative disorder in adults after solid organ and haematologic stem cell transplantation? Experience in 41 patients.实体器官移植和血液系统干细胞移植后成人移植后淋巴细胞增殖性疾病有差异吗?41例患者的经验。
Br J Radiol. 2015 Aug;88(1052):20140861. doi: 10.1259/bjr.20140861. Epub 2015 May 20.
7
Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.实体器官和造血干细胞移植后的移植后淋巴组织增生性疾病。
Leuk Lymphoma. 2019 Jan;60(1):142-150. doi: 10.1080/10428194.2018.1474462. Epub 2018 Jul 3.
8
Increased CD200 expression in post-transplant lymphoproliferative disorders correlates with an increased frequency of FoxP3(+) regulatory T cells.移植后淋巴组织增生性疾病中 CD200 表达增加与 FoxP3(+)调节性 T 细胞频率增加相关。
Ann Diagn Pathol. 2020 Oct;48:151585. doi: 10.1016/j.anndiagpath.2020.151585. Epub 2020 Aug 14.
9
Expression of intratumoral forkhead box protein 3 in posttransplant lymphoproliferative disorders: clinical features and survival outcomes.移植后淋巴细胞增殖性疾病中肿瘤内叉头框蛋白3的表达:临床特征与生存结果
Transplantation. 2015 May;99(5):1036-42. doi: 10.1097/TP.0000000000000415.
10
The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.Foxp3+/CD25+ 调节性 T 细胞和 PD-L1 表达在三阴性乳腺癌中的预测和预后价值。
Ann Diagn Pathol. 2019 Jun;40:143-151. doi: 10.1016/j.anndiagpath.2019.04.004. Epub 2019 Apr 10.

本文引用的文献

1
Successful treatment of Hodgkin lymphoma-like EBV-associated post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation with nivolumab.异基因造血干细胞移植后使用纳武单抗成功治疗霍奇金淋巴瘤样EB病毒相关移植后淋巴细胞增殖性疾病
Ann Hematol. 2020 Apr;99(4):887-889. doi: 10.1007/s00277-020-03960-4. Epub 2020 Feb 12.
2
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.波拉珠单抗维地布用于复发/难治弥漫性大 B 细胞淋巴瘤。
J Clin Oncol. 2020 Jan 10;38(2):155-165. doi: 10.1200/JCO.19.00172. Epub 2019 Nov 6.
3
The Tumor Microenvironment in Post-Transplant Lymphoproliferative Disorders.
移植后淋巴增殖性疾病中的肿瘤微环境
Cancer Microenviron. 2019 Apr;12(1):3-16. doi: 10.1007/s12307-018-00219-5. Epub 2019 Jan 24.
4
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.肿瘤微环境在 PD-L1/PD-1 介导的肿瘤免疫逃逸中的作用。
Mol Cancer. 2019 Jan 15;18(1):10. doi: 10.1186/s12943-018-0928-4.
5
Microenvironment Cell Contribution to Lymphoma Immunity.微环境细胞对淋巴瘤免疫的贡献。
Front Oncol. 2018 Jul 27;8:288. doi: 10.3389/fonc.2018.00288. eCollection 2018.
6
Understanding the tumor immune microenvironment (TIME) for effective therapy.理解肿瘤免疫微环境(TIME)以实现有效的治疗。
Nat Med. 2018 May;24(5):541-550. doi: 10.1038/s41591-018-0014-x. Epub 2018 Apr 23.
7
Restoration of Decreased T Helper 1 and CD8+ T Cell Subsets Is Associated With Regression of Lymphoproliferative Disorders Developed During Methotrexate Treatment.恢复减少的辅助性 T 细胞 1 和 CD8+T 细胞亚群与甲氨蝶呤治疗期间发生的淋巴增殖性疾病消退相关。
Front Immunol. 2018 Apr 4;9:621. doi: 10.3389/fimmu.2018.00621. eCollection 2018.
8
Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients.程序性死亡配体 1 的表达与骨髓肉瘤患者的不良预后相关。
Hematol Oncol. 2018 Aug;36(3):591-599. doi: 10.1002/hon.2506. Epub 2018 Mar 30.
9
Post-Transplantation Lymphoproliferative Disorders in Adults.成人移植后淋巴增殖性疾病
N Engl J Med. 2018 Feb 8;378(6):549-562. doi: 10.1056/NEJMra1702693.
10
Infiltration of effector regulatory T cells predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified.效应调节性T细胞浸润预示未另行指定的弥漫性大B细胞淋巴瘤预后不良。
Blood Adv. 2017 Mar 6;1(8):486-493. doi: 10.1182/bloodadvances.2016000885. eCollection 2017 Mar 14.